Experts project growth in uptake of shorter, all-oral regimens for resistant TB

Written By Jess Wiggs

This story was originally published on CIDRAP, click here to read the full article

Excerpt:

A survey of national tuberculosis (TB) program staff members projects consistent global growth in the use of shorter, all-oral drug regimens for drug-resistant TB (DR-TB), but national efforts to ensure the new treatments are accessible to eligible patients are needed, researchers reported late last week in PLOS One.

Jess Wiggs
Previous

USAID Secures $18 Million in New Funding to Accelerate Efforts to End Tuberculosis
Next

High Cure Rate with Drug-Resistant TB Regimen: Results of Operational Research in Central and Southeast Asia